Research

The URMC has a long and distinguished track record in HIV/AIDS research, dating back to the earliest days of the epidemic. UR was also a founding member of both the HIV Vaccine Trials Network (HVTN) and the AIDS Clinical Trials Group (ACTG), or their preceding organizations, and has a proud tradition of vaccine research – including the invention of ground-breaking technologies that were commercially licensed to develop the human papillomavirus (HPV) vaccines that are now used worldwide to protect against cervical and anogenital cancers.

The CFAR serves as an anchor for HIV/AIDS researchers at the URMC and a catalyst for innovation by providing leadership and infrastructure to create new interdisciplinary collaborations which result in high-impact research.